Low-Intensity Focused Ultrasound-Responsive Phase-Transitional Nanoparticles for Thrombolysis without Vascular Damage: A Synergistic Nonpharmaceutical Strategy
Source abstract
Abstract
-poly(lactic- co-glycolic acid)-PFH-CREKA nanoparticles (NPs), which combine phase transition (PT) thrombolysis capabilities with properties conducive to multimodal imaging. This well-developed PT agent responded effectively to low-intensity focused ultrasound (LIFU) by triggering the vaporization of liquid PFH to achieve thrombolysis. The presence of the CREKA peptide, which binds to the fibrin of the thrombus, allows targeted imaging and efficacious thrombolysis. Then, we found that, compared with thrombolysis using a non-phase-transition agent, PT thrombolysis can produce a robust decrease in the thrombus burden regardless of the acoustic power density of LIFU. In particular, the reduced energy for LIFU-responsive PT during the lysis process guarantees the superior safety of PT thrombolysis. After injecting the NPs intravenously, we demonstrated that this lysis process can be monitored with ultrasound and photoacoustic imaging in vivo to evaluate its efficacy. Therefore, this nonpharmaceutical strategy departs from routine methods and reveals the potential use of PT thrombolysis as an effective and noninvasive alternative to current thrombolytic therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Photoacoustic and Ultrasonic Imaging · Ultrasound and Hyperthermia Applications · Venous Thromboembolism Diagnosis and Management
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology, Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, 400010, People’s Republic of China
Chongqing Key Laboratory of Ultrasound Molecular Imaging & Department of Ultrasound, Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, 400010, People’s Republic of China
Funding
National Natural Science Foundation of China · Chongqing University
References (48)
Show source-provided references
1. 10.1161/CIR.000000000000036610.1161/CIR.0000000000000366 ↗
2. 10.1016/S0140-6736(13)61097-110.1016/S0140-6736(13)61097-1 ↗
3. 10.1161/STR.000000000000007410.1161/STR.0000000000000074 ↗
4. 10.1016/S0140-6736(14)60584-510.1016/S0140-6736(14)60584-5 ↗
5. 10.1001/jamaneurol.2015.083510.1001/jamaneurol.2015.0835 ↗
6. 10.1016/j.nbd.2010.03.00810.1016/j.nbd.2010.03.008 ↗
7. 10.1161/STROKEAHA.107.18148610.1161/STROKEAHA.107.181486 ↗
8. 10.1021/nn502995510.1021/nn5029955 ↗
9. 10.5339/gcsp.2014.4610.5339/gcsp.2014.46 ↗
10. 10.1126/science.121781510.1126/science.1217815 ↗
11. 10.1016/j.ejps.2008.06.01210.1016/j.ejps.2008.06.012 ↗
12. 10.1016/j.addr.2014.01.01210.1016/j.addr.2014.01.012 ↗
13. Rosengart A. J. · Stroke · 2004 · 35 · 299
14. 10.1364/OL.39.00259910.1364/OL.39.002599 ↗
15. 10.1002/adma.20130165510.1002/adma.201301655 ↗
16. 10.7150/thno.975410.7150/thno.9754 ↗
17. 10.7150/thno.1725110.7150/thno.17251 ↗
18. 10.1038/ncomms162710.1038/ncomms1627 ↗
19. 10.1093/jnci/djm04310.1093/jnci/djm043 ↗
20. 10.1021/acsami.7b1268910.1021/acsami.7b12689 ↗
21. 10.1073/pnas.061029810410.1073/pnas.0610298104 ↗
22. 10.1016/j.biomaterials.2013.12.03810.1016/j.biomaterials.2013.12.038 ↗
23. 10.1016/S1474-4422(03)00380-610.1016/S1474-4422(03)00380-6 ↗
24. 10.1161/STROKEAHA.110.59534810.1161/STROKEAHA.110.595348 ↗
25. 10.1016/j.addr.2009.11.00210.1016/j.addr.2009.11.002 ↗
26. 10.1039/C6BM00621C10.1039/C6BM00621C ↗
27. 10.5853/jos.2016.0090610.5853/jos.2016.00906 ↗
28. 10.1016/j.jconrel.2013.02.01510.1016/j.jconrel.2013.02.015 ↗
29. 10.1021/ja905793q10.1021/ja905793q ↗
30. 10.1063/1.486411010.1063/1.4864110 ↗
31. 10.1021/la502473w10.1021/la502473w ↗
32. 10.1016/S1474-4422(13)70091-710.1016/S1474-4422(13)70091-7 ↗
33. 10.1016/j.ultrasmedbio.2003.09.00210.1016/j.ultrasmedbio.2003.09.002 ↗
34. 10.1160/TH11-10-070510.1160/TH11-10-0705 ↗
35. 10.1016/j.ultrasmedbio.2014.12.00710.1016/j.ultrasmedbio.2014.12.007 ↗
36. 10.1016/j.jddst.2014.12.00110.1016/j.jddst.2014.12.001 ↗
37. 10.1016/j.addr.2010.05.00610.1016/j.addr.2010.05.006 ↗
38. 10.1097/RLI.000000000000005910.1097/RLI.0000000000000059 ↗
39. 10.1097/RLI.0b013e31820e143a10.1097/RLI.0b013e31820e143a ↗
40. 10.1016/j.thromres.2008.11.01910.1016/j.thromres.2008.11.019 ↗
41. 10.1001/jama.2012.348810.1001/jama.2012.3488 ↗
42. 10.1200/JCO.2016.67.456410.1200/JCO.2016.67.4564 ↗
43. 10.1056/NEJMoa05537310.1056/NEJMoa055373 ↗
44. 10.1160/TH15-12-098510.1160/TH15-12-0985 ↗
45. 10.1016/j.jacc.2009.11.09510.1016/j.jacc.2009.11.095 ↗
46. 10.1021/am406008k10.1021/am406008k ↗
47. 10.2147/IJN.S12322810.2147/IJN.S123228 ↗
48. 10.1293/tox.2017-003110.1293/tox.2017-0031 ↗